For a deeper foot or ankle target, 850 nm near-infrared light is the more plausible choice. Near-infrared wavelengths reach farther into tissue than 660 nm red light, making 850 nm the better depth-oriented option for areas associated with deeper tendon, muscle, and joint tissues.
Use 660 nm red light primarily for superficial targets, such as skin-level concerns or surface tissue. A device that combines 660 nm and 850 nm may offer coverage across both superficial and deeper tissue categories, but it has not been shown to outperform either wavelength alone for plantar heel pain, Achilles concerns, or ankle and foot tendon recovery.
Choose by Target Depth, Not by the Body-Part Name
"Foot" and "ankle" are not single-depth treatment areas. The right wavelength depends less on the diagnosis label and more on whether the intended target is near the surface or beneath it.
| Intended Target Category | More Plausible Wavelength Choice | Why |
|---|---|---|
| Surface skin or superficial tissue | 660 nm red light | Red light is predominantly absorbed in more superficial tissue layers. |
| Deeper tendon-, muscle-, joint-, or nerve-related tissue | 850 nm near-infrared light | Near-infrared wavelengths are used for deeper targets because they penetrate farther than red light. |
| Both surface and deeper target categories | 660 nm plus 850 nm | A combination can reasonably be viewed as broader depth coverage, not as proven superior treatment. |
General soft-tissue estimates illustrate the difference. Light around 660 nm is commonly described as reaching roughly 0.5--2.5 mm into soft tissue, while near-infrared light in the 780--810 nm range may reach about 8--10 mm into deeper layers such as muscle. Broader photobiomodulation guidance similarly distinguishes shorter wavelengths, roughly 600--700 nm, for superficial tissue from longer wavelengths, roughly 780--950 nm, for deeper tissue.
That does not mean every deep-feeling foot problem is reachable with light, or that reaching a depth guarantees a meaningful clinical effect. It does establish the practical selection rule: if the intended target is beneath the skin, favor 850 nm rather than 660 nm.
Applying That Rule to Foot and Ankle Areas
For foot and ankle use, think in categories rather than assuming one wavelength fits every location.
Surface-Level Targets
A 660 nm option is the more logical match when the concern is centered on superficial skin or surface tissue. In broader foot-related guidance, 660 nm is associated with surface wounds and skin conditions.
This is a depth-based distinction, not a diagnosis or healing claim. A skin-level target may be physically more accessible to red light, but that does not establish that red light will resolve the underlying cause of discomfort or a skin problem.
Deeper Targets
An 850 nm option is more aligned with areas where the intended target lies beneath the skin, including tissue associated with:
- The Achilles tendon insertion
- The ankle joint region
- Deeper muscle-related tissue
- Deeper nerve-related tissue
- Deeper plantar or heel structures
One foot-specific synthesis estimates 810--850 nm penetration at approximately 18--35 mm in the foot and identifies deeper structures such as ankle joint spaces, deep nerves, and the Achilles insertion as potential depth-oriented targets. However, those figures are estimates assembled from general penetration information and assumed tissue thickness---not direct measurements in every foot or ankle.
They should not be treated as a placement map, a guarantee that light reaches a particular structure, or a reason to assume light can work effectively through bone.
Why 850 nm is More Suitable for Deep Support
The central difference is not that 850 nm is inherently "stronger." It is that near-infrared light is less limited to the superficial layers than visible red light.
At 660 nm, red light is readily absorbed by blood and skin components. General tissue measurements describe its penetration as under 10 mm, with a substantial loss of intensity as it travels deeper. Near-infrared wavelengths penetrate farther, which is why wavelengths around 810--850 nm are generally used when the target is deeper than the dermis.
For a deep ankle or tendon-related target, that makes 850 nm the better-supported physical choice. It is still only a depth rationale. It is not proof that 850 nm produces better pain relief, tendon recovery, tissue healing, or structural improvement for a particular foot or ankle concern.
Detectable light is not the same as a therapeutic dose. In layered human tissue, 660 nm light has been detected at substantial depths under particular experimental conditions. That finding does not show that enough energy reached a deep foot or ankle structure to produce a therapeutic effect.
This distinction matters because penetration claims can sound more conclusive than they are. A photon may be measurable at depth while the delivered amount is too low, too variable, or not clinically meaningful for the intended target.
When a Dual-Wavelength Approach Makes Sense
A 660 nm plus 850 nm approach is reasonable when the goal is simply to cover two tissue-depth categories:
- 660 nm for superficial skin and surface tissue
- 850 nm for deeper tissue categories
That is a practical rationale for combination devices. It is not evidence that using both wavelengths will produce better results than using 850 nm alone for a deep target.
There is no direct human head-to-head evidence in the available foot and ankle research showing that 660 nm is superior to 850 nm---or that a combined approach is superior to either one---for:
- Plantar heel pain
- Achilles tendinopathy
- Ankle or foot tendon recovery
If the target is clearly deep, 850 nm remains the simpler choice. If there is also a distinct surface-level target, adding 660 nm may provide superficial coverage without changing the fact that 850 nm is the depth-oriented wavelength.
Keep Clinical Expectations Separate From Penetration
Some human research suggests photobiomodulation may help with selected foot and ankle conditions, including plantar fasciitis and ankle sprain. However, the evidence base is limited, and results differ by condition and outcome. For example, available findings suggest possible pain benefit in some contexts, while support for outcomes such as swelling or function is less certain.
This means light-based use should be viewed, if used at all, as a possible adjunct---not proof of recovery from an injury or structural problem.
Avoid treating wavelength selection as evidence that light can:
- Repair a torn tendon or ligament
- Correct a joint or bone problem
- Confirm the cause of heel, foot, or ankle pain
- Replace clinical assessment for persistent, severe, or worsening symptoms
Diabetic foot-ulcer research also does not settle the 660 nm versus 850 nm question for deeper foot and ankle tissue. Both 660 nm and 850/890 nm appear in foot-ulcer research, but ulcer healing is a different clinical question from tendon, plantar fascia, heel, or ankle-joint support. One cited diabetic-foot record is specifically a protocol for a randomized, controlled, double-blind clinical trial, rather than a report of clinical outcome results.
For a straightforward decision, choose 850 nm when your intended foot or ankle target is deeper than the skin. Choose 660 nm for superficial skin-level targets. Consider both only when you deliberately want coverage at both levels---and not because a combined wavelength setup has been proven better for deep foot or ankle recovery.
Small
Moderate
Moderate
Moderate
Full
